EDESA BIOTECH INC (EDSA) Stock Price & Overview
NASDAQ:EDSA • CA27966L3065
The current stock price of EDSA is 6.52 USD. Today EDSA is up by 80.61%. In the past month the price increased by 482.14%. In the past year, price increased by 179.83%.
EDSA Key Statistics
- Market Cap
- 54.312M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.15
- Dividend Yield
- N/A
EDSA Stock Performance
EDSA Stock Chart
EDSA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to EDSA. When comparing the yearly performance of all stocks, EDSA is one of the better performing stocks in the market, outperforming 99.06% of all stocks.
EDSA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EDSA. While EDSA has a great health rating, there are worries on its profitability.
EDSA Earnings
EDSA Forecast & Estimates
8 analysts have analysed EDSA and the average price target is 11.22 USD. This implies a price increase of 72.09% is expected in the next year compared to the current price of 6.52.
EDSA Groups
Sector & Classification
EDSA Financial Highlights
Over the last trailing twelve months EDSA reported a non-GAAP Earnings per Share(EPS) of -1.15. The EPS increased by 38.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.13% | ||
| ROE | -56.01% | ||
| Debt/Equity | 0 |
EDSA Ownership
EDSA Latest News, Press Relases and Analysis
EDSA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.85 | 410.651B | ||
| AMGN | AMGEN INC | 16.4 | 197.945B | ||
| GILD | GILEAD SCIENCES INC | 16.14 | 180.072B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 116.919B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.36 | 80.868B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.87 | 42.343B | ||
| INSM | INSMED INC | N/A | 30.619B | ||
| NTRA | NATERA INC | N/A | 27.941B | ||
| BIIB | BIOGEN INC | 12.15 | 27.603B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 21.26B | ||
| MRNA | MODERNA INC | N/A | 21.03B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.746B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.715B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EDSA
Company Profile
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. The company is headquartered in Markham, Ontario and currently employs 17 full-time employees. The company went IPO on 2008-08-25. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Company Info
EDESA BIOTECH INC
100 Spy Crt
Markham ONTARIO L3R 5H6 CA
CEO: Pardeep Nijhawan
Employees: 17
Phone: 19054751234
EDESA BIOTECH INC / EDSA FAQ
What does EDSA do?
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. The company is headquartered in Markham, Ontario and currently employs 17 full-time employees. The company went IPO on 2008-08-25. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Can you provide the latest stock price for EDESA BIOTECH INC?
The current stock price of EDSA is 6.52 USD. The price increased by 80.61% in the last trading session.
Does EDSA stock pay dividends?
EDSA does not pay a dividend.
How is the ChartMill rating for EDESA BIOTECH INC?
EDSA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy EDSA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EDSA.
What is the employee count for EDSA stock?
EDESA BIOTECH INC (EDSA) currently has 17 employees.
Can you provide the market cap for EDESA BIOTECH INC?
EDESA BIOTECH INC (EDSA) has a market capitalization of 54.31M USD. This makes EDSA a Micro Cap stock.